AVGR - Avinger, Inc.
| Previous Close | 1.63 |
| Open | 1.63 |
| Bid | 1.60 x 1000 |
| Ask | 1.72 x 1000 |
| Day's Range | 1.57 - 1.69 |
| 52 Week Range | 0.95 - 38.24 |
| Volume | 373,062 |
| Avg. Volume | 1,968,168 |
| Market Cap | 8.901M |
| Beta | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -49.25 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- GlobeNewswire•3 days ago
Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics (C3) 2018
Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at Complex Cardiovascular Catheter Therapeutics (C3) 2018 in Orlando, Florida. Ocelot combines real-time image guidance using optical coherence tomography (OCT) with a proprietary CTO crossing catheter design to aid physicians in the treatment of chronic total occlusions. Dr. Mahir Elder, an interventional cardiologist at the Detroit Medical Center Cardiovascular Institute, performed the case.
- GlobeNewswire•10 days ago
Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound
Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. OCT is a light-based, high definition imaging modality, which generates no X-ray radiation. Avinger’s proprietary Lumivascular technology utilizes OCT to provide real-time intravascular imaging during the treatment of peripheral artery disease.
- GlobeNewswire•11 days ago
Avinger Appoints Mark Weinswig as Chief Financial Officer
Avinger, Inc. (AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer (CFO) effective June 25, 2018. Mr. Weinswig will succeed Matt Ferguson, who will be leaving the Company to pursue other opportunities. Mr. Ferguson will remain a full-time employee of Avinger until August 1, 2018, and continue as a consultant through December 31, 2018, to ensure a smooth transition.
- Simply Wall St.•13 days ago
Loss-Making Avinger Inc (NASDAQ:AVGR) Expected To Breakeven
Avinger Inc’s (NASDAQ:AVGR): Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) inRead More...
- GlobeNewswire•25 days ago
Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, Calif., May 30, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today announced a schedule of sessions and posters highlighting the company’ ...
- GlobeNewswire•26 days ago
Avinger to Present at the 8th Annual LD Micro Invitational
REDWOOD CITY, Calif., May 29, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, announced today that it will be presenting at the 8 th Annual LD Micro Invitational ...
- ACCESSWIRE•26 days ago
Complimentary Technical Snapshots on Avinger and Three More Medical Equipment Stocks
Under evaluation this morning are these four stocks: Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), Corindus Vascular Robotics Inc. (NYSE AMER: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Redwood City, California headquartered Avinger Inc.'s stock finished last Friday's session 2.03% higher at $2.01.
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Avinger and Cara Therapeutics
NEW YORK, NY / ACCESSWIRE / May 24, 2018 / Avinger, Inc. and Cara Therapeutics were both exploding in Wednesday trading on positive news. Avinger shares blasted off after the company announced it had gained ...
- InvestorPlace•last month
Avinger Inc Stock Goes Gangbusters on FDA Approval of Next-Gen Medical Device
The device that is sending Avinger Inc stock soaring with its FDA approval is the Pantheris Lumivascular atherectomy system. This system allows physicians to treat peripheral artery disease in a more accurate way than previous methods. The Pantheris Lumivascular atherectomy system makes better treatment possible by allowing for real-time intravascular imaging of arteries.
- GlobeNewswire•last month
Avinger Receives FDA Clearance of Next Generation Pantheris Device
Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment of peripheral artery disease. Lumivascular is the only technology that combines real-time intravascular imaging with highly effective catheters for the treatment of PAD.
- Simply Wall St.•last month
What Investors Should Know About Avinger Inc’s (NASDAQ:AVGR) Financial Strength
While small-cap stocks, such as Avinger Inc (NASDAQ:AVGR) with its market cap of US$6.39M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of AVGR earnings conference call or presentation 14-May-18 8:30pm GMT
Q1 2018 Avinger Inc Earnings Call
- Associated Press•last month
Avinger: 1Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of $5.37. The medical device maker posted revenue of $1.8 million in the period. In the final minutes of trading on Monday, ...
- GlobeNewswire•last month
Avinger Announces First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 14, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today reported results for the first quarter ended March 31, 2018.. First ...
- ACCESSWIRE•last month
Avinger, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Avinger, Inc. (NASDAQ: AVGR ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern Time. To listen ...
- GlobeNewswire•2 months ago
Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018
REDWOOD CITY, Calif., May 04, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today announced that it will release its financial results for the first ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Avinger and VIVUS
NEW YORK, NY / ACCESSWIRE / May 2, 2018 / Positive developments sent shares of both Avinger and VIVUS higher on Tuesday. Avinger announced that its next generationPantheris Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross International Symposium 2018. VIVUS announced that it has entered into a definitive agreement for the acquisition of PANCREAZE.
- GlobeNewswire•2 months ago
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018
REDWOOD CITY, Calif., April 30, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, announced that its next generation Pantheris ® Lumivascular atherectomy ...
- ACCESSWIRE•3 months ago
2 Emerging Technology Stocks That Could Spark New Industry Trends
CORAL GABLES, FL / ACCESSWIRE / March 29, 2018 / U.S. index futures jumped on Thursday. Investors await key inflation data and technology stocks have seen a recovery during the early part of the premarket ...
- GlobeNewswire•3 months ago
Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
REDWOOD CITY, Calif., March 29, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today announced that Arne Schwindt, M.D., a vascular surgeon at St. Franziskus ...
- ACCESSWIRE•3 months ago
Blog Exposure - InspireMD Announced Regulatory Approval for CGuard Embolic Prevention System and MGuard Prime in Peru
Stock Monitor: Avinger Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on InspireMD, Inc. (NYSE: NSPR ). If you want access ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AVGR earnings conference call or presentation 19-Mar-18 8:30pm GMT
Q4 2017 Avinger Inc Earnings Call
- Associated Press•3 months ago
Avinger reports 4Q loss
The Redwood City, California-based company said it had a loss of $12.58 per share. Losses, adjusted for non-recurring costs and restructuring costs, were $9.97 per share. The medical device maker posted ...
